Thymic factor therapy for herpetic keratitis.
Thirty patients with herpetic keratitis were allocated to a double-blind trial with either local treatment plus placebo (control group) or local treatment plus thymostimulin (TS group). The follow-up at 24 months demonstrated a significant reduction of recurrence rate among patients receiving thymostimulin, along with a significant increase of sheep rosette-forming cells (E rosette). Furthermore, among patients with superficial keratitis, thymostimulin treatment resulted in a significantly quicker corneal re-epithelization than placebo. Thymostimulin seems to be a safe and helpful drug in the management of herpetic keratitis.
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006561:Herpes Simplex; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D007634:Keratitis / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology / Q000503:physiopathology; D007694:Killer Cells, Natural / Q000502:physiology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012397:Rosette Formation; D012882:Skin Tests; D013949:Thymus Extracts / Q000627:therapeutic use*; D013997:Time Factors
D007136:Immunoglobulins; D013949:Thymus Extracts; C031407:thymostimulin